Table 4

Common TEAEs (≥3% in any treatment group) in the PBO-controlled period up to week 12

FIL 200 mg
N=777
FIL 100 mg
N=788
PBO
N=781
Nasopharyngitis, n (%)27 (3.5)19 (2.4)19 (2.4)
Upper respiratory tract infection, n (%)26 (3.3)20 (2.5)14 (1.8)
Nausea, n (%)27 (3.5)18 (2.3)13 (1.7)
  • FIL, filgotinib; PBO, placebo; TEAE, treatment-emergent adverse event.